GDTC
CytoMed Therapeutics Limited Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.30M
P/E Ratio
—
EPS
$-0.27
Beta
0.05
52W High
$3.68
52W Low
$0.68
50-Day MA
$0.90
200-Day MA
$1.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
Fundamentals
| Revenue (TTM) | 860,850 |
| Gross Profit (TTM) | 771,090 |
| EBITDA | $-3.85M |
| Operating Margin | -535.00% |
| Return on Equity | -50.30% |
| Return on Assets | -29.30% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.43 |
| Price-to-Book | 2.10 |
| Price-to-Sales (TTM) | 13.13 |
| EV/Revenue | 37.33 |
| EV/EBITDA | -4.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 46.90% |
| Shares Outstanding | $11.83M |
| Float | $3.49M |
| % Insiders | 70.47% |
| % Institutions | 0.14% |
Historical Volatility
HV 10-Day
95.05%
HV 20-Day
80.51%
HV 30-Day
92.03%
HV 60-Day
84.58%
HV Rank
57.9%
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GDTC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026